370 related articles for article (PubMed ID: 26422675)
1. Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome.
Rosa GM; Ferrero S; Nitti VW; Wagg A; Saleem T; Chapple CR
Eur Urol; 2016 Feb; 69(2):311-23. PubMed ID: 26422675
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.
Michel MC; Gravas S
Expert Opin Drug Saf; 2016 May; 15(5):647-57. PubMed ID: 26954275
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular effects of antimuscarinic agents and beta3-adrenergic receptor agonist for the treatment of overactive bladder.
Rosa GM; Baccino D; Valbusa A; Scala C; Barra F; Brunelli C; Ferrero S
Expert Opin Drug Saf; 2018 May; 17(5):487-497. PubMed ID: 29542337
[TBL] [Abstract][Full Text] [Related]
4. A drug safety evaluation of mirabegron in the management of overactive bladder.
Robinson D; Thiagamoorthy G; Cardozo L
Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
[TBL] [Abstract][Full Text] [Related]
5. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
[TBL] [Abstract][Full Text] [Related]
6. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.
Ohlstein EH; von Keitz A; Michel MC
Eur Urol; 2012 Nov; 62(5):834-40. PubMed ID: 22695239
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).
Drake MJ; MacDiarmid S; Chapple CR; Esen A; Athanasiou S; Cambronero Santos J; Mitcheson D; Herschorn S; Siddiqui E; Huang M; Stoelzel M
Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28419650
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
[TBL] [Abstract][Full Text] [Related]
11. Selective β₃-adrenoceptor agonists for the treatment of overactive bladder.
Andersson KE; Martin N; Nitti V
J Urol; 2013 Oct; 190(4):1173-80. PubMed ID: 23458471
[TBL] [Abstract][Full Text] [Related]
12. Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB).
Rossanese M; Novara G; Challacombe B; Iannetti A; Dasgupta P; Ficarra V
BJU Int; 2015 Jan; 115(1):32-40. PubMed ID: 24602031
[TBL] [Abstract][Full Text] [Related]
13. Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.
Giarenis I; Robinson D; Cardozo L
Drugs; 2015 Oct; 75(15):1707-13. PubMed ID: 26323339
[TBL] [Abstract][Full Text] [Related]
14. β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.
Otsuki H; Kosaka T; Nakamura K; Mishima J; Kuwahara Y; Tsukamoto T
Int Urol Nephrol; 2013 Feb; 45(1):53-60. PubMed ID: 23212147
[TBL] [Abstract][Full Text] [Related]
15. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E
Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
[TBL] [Abstract][Full Text] [Related]
17. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.
Chapple CR; Siddiqui E
Expert Rev Clin Pharmacol; 2017 Feb; 10(2):131-151. PubMed ID: 28001447
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes with the β
Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
[TBL] [Abstract][Full Text] [Related]
19. Mirabegron for the treatment of overactive bladder.
Gras J
Drugs Today (Barc); 2012 Jan; 48(1):25-32. PubMed ID: 22384458
[TBL] [Abstract][Full Text] [Related]
20. Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β
Yamaguchi O; Ikeda Y; Ohkawa S
Low Urin Tract Symptoms; 2017 Jan; 9(1):38-45. PubMed ID: 28120446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
